期刊文献+

重组腺相关病毒载体诱导的天然免疫反应及机制 被引量:7

Innate immune mechanisms against recombinant adeno-associated virus vectors——A review
原文传递
导出
摘要 重组腺相关病毒(rAAV)已成为基因治疗领域应用最广泛的载体之一。临床前研究显示其具有很高的安全性,但人体免疫毒性仍是制约其临床疗效的关键,因此有关rAAV免疫机制的研究成为近期热点。尽管天然免疫在获得性免疫反应中发挥重要作用,但与rAAV有关的天然免疫研究过去一直未被重视。直到最近,才确认有至少3种人体细胞(树突状细胞、巨噬细胞和内皮细胞)参与了rAAV的天然免疫,作用机制为可识别载体基因组的TLR9或病毒衣壳TLR2所介导,NF-κB或干扰素调节因子(IRFs)信号通路被激活,导致各种炎性因子及I型干扰素的大量表达。自身互补型rAAV诱导的TLR9依赖性天然免疫较单链rAAV更为强烈。本文重点对近期发现的激活天然免疫反应的宿主与rAAV的相互作用、涉及的信号通路、天然免疫对获得性免疫以及转基因表达的影响进行综述。 Recombinant adeno-associated virus(rAAV) is one of the most commonly used vectors for gene therapy.Despite the promising safety profile demonstrated in preclinical trials,the clinic efficacy of using rAAV was hampered by undesired response from the immune system.It is important to understand the mechanisms that lead to the induction of immune response against rAAV.Although a crucial role for innate immunity is shaping adaptive immune responses,the innate immune to rAAV was ignored in the past.Till now,at least three human cell types(dendritic cells,macrophages and endothelial cells) were discovered to be involved in sensing rAAV infection.The engagement of TLR9 by rAAV vector genomes triggers the activation of NF-κB signaling cascades,leading to the induction of pro-inflammatory cytokine genes.The viral capsid components are detected by TLR2,and this leads to the production of type I interferon mediated by interferon regulatory factors(IRFs) pathway.Self-complementary rAAV vectors induced higher TLR9 dependent innate immune response than single stranded rAAV.This review highlights the recent findings regarding the innate immune responses to rAAV vectors,the signaling pathways involved,and the impacts of innate immunity on the adaptive immune response to rAAV and its transgene expression.
作者 刁勇 许瑞安
出处 《微生物学报》 CAS CSCD 北大核心 2012年第5期550-557,共8页 Acta Microbiologica Sinica
基金 国家“863计划”(2008AA02Z135) 国家科技重大专项(2009ZX09103-643) 国家自然科学基金(30973591)~~
关键词 重组腺相关病毒 基因治疗 免疫 信号通路 recombinant adeno-associated virus gene therapy immunology signal pathway
  • 相关文献

参考文献36

  • 1Mays LE, Wilson JM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Molecular Therapy, 2011, 19( 1 ) :16-27.
  • 2Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Therapy, 2008, 15 ( 11 ) :808-816.
  • 3Mingozzi F, High KA. Immune responses to AAV in clinical trials. Current Gene Therapy, 2011, 1l (4) : 321-330.
  • 4Kawai T, Akira S. Innate immune recognition of viral infection. Nature Immunology, 2006, 7 (2) : 131-137.
  • 5McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. Journal of Virology, 2005, 79 ( 1 ) : 17-27.
  • 6Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy, 2010, 2( 1 ) :37-56.
  • 7Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeuo-associated virus gene therapy vectors in mice. The Journal of Clinical Investigation, 2009, 119(8) :2388-2398.
  • 8Hsel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, Gillen S, Kleeff J, Stabenow D, Odenthal M, Knolle P, Hallek M, Protzer U, Biining H. TLR2-mediated innate immune response in human non-parenchymal liver cells towards adeno-associated viral (AAV) vectors. Hepatology, 2012, 55(1 ): 287- 297.
  • 9Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ert| HC, Muruve DA, Lee B, Herzog RW. The genome of self-complementary adeno- associated viral vectors increases Toll-like receptor 9- dependent innate immune responses in the liver. Blood, 2011,117 ( 24 ) :6459-6468.
  • 10Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nature lmmunolology, 2009,10( 11 ) : 1200-1207.

二级参考文献35

  • 1Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Meal, 2006, 12(3): 342 347.
  • 2Mingozzi F, Maus MV, Hui DJ, et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Meal, 2007, 13(4): 419-422.
  • 3Madsen D, Cantwell ER, O'Brien T, et al. Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VPI. J Gen Virol, 2009, 90(11): 2622-2633.
  • 4Wright JF. Transient transfection methods for clinical adeno-associated viral vector production. Hum Gene Ther, 2009, 20(7): 698-706.
  • 5Chadeuf G, Ciron C, Moullier P, et al. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol Ther, 2005, 12(4): 744- 753.
  • 6Li CW, Hirch M, Asokan A, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector transduced cells coexpressing the AAV2 capsid in vivo. J Virol, 2007, 81(14): 7540-7547.
  • 7Wang LL, Figueredo J, Calcedo R, et al. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T-cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther, 2007, 18(3): 185-194.
  • 8Wang XS, Khuntirat B, Qing K, et al. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol, 1998, 72(7):5472-5480.
  • 9Nony P, Chadeuf G, Tessier J, et al. Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J Virol, 2003, 77(1): 776-781.
  • 10Allen JM, Debelak DJ, Reynolds TC, et al. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol, 1997, 71(9): 6816-6822.

共引文献11

同被引文献131

  • 1张德莉,朱圣姬,罗光富,黄应平,袁丁,刘立明.自由基与DNA氧化损伤的研究进展[J].三峡大学学报(自然科学版),2004,26(6):563-567. 被引量:36
  • 2Yong Diao,Jian Ma,Wei-Dong Xiao,Jia Luo,Xin-Yan Li,Kin-Wah Chu,Peter WC Fung,Nagy Habib,Farzin Farzaneh,Rui-An Xu.Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin[J].World Journal of Gastroenterology,2007,13(34):4615-4619. 被引量:15
  • 3Daya S, Betas KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev, 2008, 21(4): 583-93.
  • 4Girod A, Wobus CE, Zadori Z, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol, 2002, 83(5): 973-8.
  • 5Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther, 2012, 19(6): 649-58.
  • 6Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno- associated viruses. J Infect Dis, 2009, 199(3): 381-90.
  • 7Calcedo R, Morizono H, Wang L, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol, 2011, 18(9): 1586-8.
  • 8Schlehofer JR, Boeke C, Reuland M, et al. Presence of DNA of adeno-associated virus in subfertile couples, but no association with fertility factors. Hum Reprod, 2012, 7(3): 770-8.
  • 9Alam S, Meyers C. Adeno-associated virus type 2 induces apoptosis in human papillomavirus-infected cell lines but not in normal keratinocytes. J Virol, 2009, 83(19): 10286- 92.
  • 10Alam S, Bowser BS, Conway M J, et al. Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells. Mol Cancer, 2011, 10:97.

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部